Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24N2O2.2C6H8O6 |
Molecular Weight | 676.665 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO.[H][C@@]2(OC(=O)C(O)=C2O)[C@@H](O)CO.[H][C@]3(C[C@@H]4CCN3C[C@@H]4C=C)[C@H](O)C5=C6C=C(OC)C=CC6=NC=C5
InChI
InChIKey=CJHQUYQRCLIWSW-JPGAVJPLSA-N
InChI=1S/C20H24N2O2.2C6H8O6/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;2*7-1-2(8)5-3(9)4(10)6(11)12-5/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;2*2,5,7-10H,1H2/t13-,14-,19-,20+;2*2-,5+/m000/s1
Molecular Formula | C20H24N2O2 |
Molecular Weight | 324.4168 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C6H8O6 |
Molecular Weight | 176.1241 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Quinine ascorbate is a salt of antimalarial drug quinine and ascorbic acid (vitamin C). Ascorbate reduces the potency of quinolone-containing anti-malarial drugs. Quinine ascorbate was marketed as a component of over-the-counter smoking deterrent products but was not recognized as safe by the FDA regulation in 1993.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.6 μg/mL |
300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
9.7 μg/mL |
300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
10.3 μg/mL |
300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
11.3 μg/mL |
300 mg/m² 2 times / day multiple, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: MULTIPLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
3.2 μg/mL |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE unknown | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
8.4 μg/mL |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE unknown | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
87.2 μg × h/mL |
300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
90.5 μg × h/mL |
300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
95.4 μg × h/mL |
300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
28 μg × h/mL |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE unknown | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
73 μg × h/mL |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE unknown | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.4 h |
300 mg/m² single, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
12.5 h |
300 mg/m² single, intravenous dose: 300 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
13.1 h |
300 mg/m² single, intragastric dose: 300 mg/m² route of administration: Intragastric experiment type: SINGLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
|
9.8 h |
300 mg/m² 2 times / day multiple, intramuscular dose: 300 mg/m² route of administration: Intramuscular experiment type: MULTIPLE co-administered: |
QUININE serum | Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [Inhibition 20 uM] | ||||
no [Inhibition 20 uM] | ||||
weak | ||||
yes [IC50 1.8 uM] | ||||
yes [IC50 22.6 uM] | ||||
yes [IC50 51.6 uM] | ||||
yes [Inhibition 20 uM] | ||||
yes [Inhibition 80 uM] | ||||
yes [Ki 3.4 uM] | ||||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
likely | ||||
likely | ||||
yes [Km 10 uM] | ||||
yes [Km 2.6 uM] | ||||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00468 |
yes | |||
yes | yes (co-administration study) Comment: Coadministration of Ketoconazole increased Quinine AUC by 45% and decreased a mean oral clearance of Quinine by 31%. |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:45:14 GMT 2023
by
admin
on
Fri Dec 15 18:45:14 GMT 2023
|
Record UNII |
KAU4V10S2I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.547
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
||
|
CFR |
21 CFR 310.544
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C152127
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | |||
|
56840788
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | |||
|
KAU4V10S2I
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | |||
|
146-40-7
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | |||
|
236327
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
205-671-5
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL170
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY | |||
|
DTXSID70932743
Created by
admin on Fri Dec 15 18:45:14 GMT 2023 , Edited by admin on Fri Dec 15 18:45:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |